Promoting remyelination in multiple sclerosis: Current drugs and future prospects

Multiple Sclerosis Journal

Volumn 21, Issue 5, 2015, Pages 541-549

  Kremer, David ^a   Küry, Patrick ^b   Dutta, Ranjan ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b Department of Neurology   (Germany)

Author keywords

Multiple sclerosis; remyelination; therapy; trials

Indexed keywords

ANTIHISTAMINIC AGENT; BENZATROPINE; CLEMASTINE; FINGOLIMOD; IMMUNOGLOBULIN M ANTIBODY; OLESOXIME; QUERCETIN; QUETIAPINE; CENTRAL NERVOUS SYSTEM AGENTS; GSK 239512; HUMANIZED ANTIBODY GNBAC1; IRX 4204; LINGO 1 ANTIBODY; RECOMBINANT HUMAN MONOCLONAL IGM ANTIBODY 22; UNCLASSIFIED DRUG; VX 15 2503;

FOOD AND DRUG ADMINISTRATION; HUMAN; MULTIPLE SCLEROSIS; OLIGODENDROGLIAL PRECURSOR CELL; REGENERATION; REMYELINIZATION; REVIEW; STEM CELL; UNITED STATES; DRUG APPROVAL; EUROPEAN MEDICINES AGENCY; NERVE REGENERATION; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); DRUG EFFECTS; MYELIN SHEATH; OLIGODENDROGLIA; PATHOLOGY;

HUMANS; MULTIPLE SCLEROSIS; MYELIN SHEATH; NERVE REGENERATION; OLIGODENDROGLIA;

EID: 84938484098     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458514566419     Document Type: Review

References (58)

1. Charcot JM. Histologie de la sclerose en plaques. Gaz Hosp. 1868 ; 41: 554-555
2. Calabresi PA, Kieseier BC, Arnold DL, et al. Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): A randomised, phase 3, double-blind study. Lancet Neurol. 2014 ; 13: 657-665
3. Cocco E, Sardu C, Spinicci G, et al. Influence of treatments in multiple sclerosis disability: A cohort study. Mult Scler. 2014 ;:
4. Comi G. Disease-modifying treatments for progressive multiple sclerosis. Mult Scler. 2013 ; 19: 1428-1436
5. Trapp BD, Nave KA. Multiple sclerosis: An immune or neurodegenerative disorder?. Annu Rev Neurosci. 2008 ; 31: 247-269
6. Trapp BD, Stys PK. Virtual hypoxia and chronic necrosis of demyelinated axons in multiple sclerosis. Lancet Neurol. 2009 ; 8: 280-291
7. Lassmann H. New concepts on progressive multiple sclerosis. Curr Neurol Neurosci Rep. 2007 ; 7: 239-244
8. Lassmann H, van Horssen J, Mahad D. Progressive multiple sclerosis: Pathology and pathogenesis. Nat Rev Neurol. 2012 ; 8: 647-656
9. Franklin RJ, ffrench-Constant C, Edgar JM, et al. Neuroprotection and repair in multiple sclerosis. Nat Rev Neurol. 2012 ; 8: 624-634
10. Chang A, Nishiyama A, Peterson J, et al. NG2-positive oligodendrocyte progenitor cells in adult human brain and multiple sclerosis lesions. J Neurosci. 2000 ; 20: 6404-6412
11. Chang A, Tourtellotte WW, Rudick R, et al. Premyelinating oligodendrocytes in chronic lesions of multiple sclerosis. N Engl J Med. 2002 ; 346: 165-173
12. Chang A, Staugaitis SM, Dutta R, et al. Cortical remyelination: A new target for repair therapies in multiple sclerosis. Ann Neurol. 2012 ; 72: 918-926
13. Prineas JW, Connell F. Remyelination in multiple sclerosis. Ann Neurol. 1979 ; 5: 22-31
14. Kremer D, Aktas O, Hartung HP, et al. The complex world of oligodendroglial differentiation inhibitors. Ann Neurol. 2011 ; 69: 602-618
15. Ntziachristos P, Lim JS, Sage J, et al. From fly wings to targeted cancer therapies: A centennial for notch signaling. Cancer Cell. 2014 ; 25: 318-334
16. John GR, Shankar SL, Shafit-Zagardo B, et al. Multiple sclerosis: Re-expression of a developmental pathway that restricts oligodendrocyte maturation. Nat Med. 2002 ; 8: 1115-1121
17. Wang S, Sdrulla AD, diSibio G, et al. Notch receptor activation inhibits oligodendrocyte differentiation. Neuron. 1998 ; 21: 63-75
18. Hu QD, Ang BT, Karsak M, et al. F3/contactin acts as a functional ligand for Notch during oligodendrocyte maturation. Cell. 2003 ; 115: 163-175
19. Matloubian M, Lo CG, Cinamon G, et al. Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature. 2004 ; 427: 355-360
20. Miron VE, Schubart A, Antel JP. Central nervous system-directed effects of FTY720 (fingolimod). J Neurol Sci. 2008 ; 274: 13-17
21. Jung CG, Kim HJ, Miron VE, et al. Functional consequences of S1P receptor modulation in rat oligodendroglial lineage cells. Glia. 2007 ; 55: 1656-1667
22. Miron VE, Ludwin SK, Darlington PJ, et al. Fingolimod (FTY720) enhances remyelination following demyelination of organotypic cerebellar slices. Am J Pathol. 2010 ; 176: 2682-2694
23. Choi JW, Gardell SE, Herr DR, et al. FTY720 (fingolimod) efficacy in an animal model of multiple sclerosis requires astrocyte sphingosine 1-phosphate receptor 1 (S1P1) modulation. Proc Natl Acad Sci U S A. 2011 ; 108: 751-756
24. van Doorn R, Nijland PG, Dekker N, et al. Fingolimod attenuates ceramide-induced blood-brain barrier dysfunction in multiple sclerosis by targeting reactive astrocytes. Acta Neuropathol. 2012 ; 124: 397-410
25. Deshmukh VA, Tardif V, Lyssiotis CA, et al. A regenerative approach to the treatment of multiple sclerosis. Nature. 2013 ; 502: 327-332
26. Mi S, Miller RH, Lee X, et al. LINGO-1 negatively regulates myelination by oligodendrocytes. Nat Neurosci. 2005 ; 8: 745-751
27. Mi S, Pepinsky RB, Cadavid D. Blocking LINGO-1 as a therapy to promote CNS repair: From concept to the clinic. CNS Drugs. 2013 ; 27: 493-503
28. Warrington AE, Bieber AJ, Ciric B, et al. A recombinant human IgM promotes myelin repair after a single, very low dose. J Neurosci Res. 2007 ; 85: 967-976
29. Watzlawik JO, Wootla B, Painter MM, et al. Cellular targets and mechanistic strategies of remyelination-promoting IgMs as part of the naturally occurring autoantibody repertoire. Expert Rev Neurother. 2013 ; 13: 1017-1029
30. Feschotte C, Gilbert C. Endogenous viruses: Insights into viral evolution and impact on host biology. Nat Rev Genet. 2012 ; 13: 283-296
31. Perron H, Lang A. The human endogenous retrovirus link between genes and environment in multiple sclerosis and in multifactorial diseases associating neuroinflammation. Clin Rev Allergy Immunol. 2010 ; 39: 51-61
32. Rasmussen HB, Geny C, Deforges L, et al. Expression of endogenous retroviruses in blood mononuclear cells and brain tissue from multiple sclerosis patients. Acta Neurol Scand Suppl. 1997 ; 169: 38-44
33. Kremer D, Schichel T, Förster M, et al. Human endogenous retrovirus type W envelope protein inhibits oligodendroglial precursor cell differentiation. Ann Neurol. 2013 ; 74: 721-732
34. Kremer D, Förster M, Schichel T, et al. The neutralizing antibody GNbAC1 abrogates HERV-W envelope protein-mediated oligodendroglial maturation blockade. Mult Scler. 2014 ;:
35. Derfuss T, Curtin F, Lang A, et al. GNbAC1, a humanized monoclonal antibody against the multiple sclerosis associated retrovirus envelope protein, is well tolerated in patients with multiple sclerosis (P2.217). Neurology. 2014 ; 82: P2.217
36. Bi X, Zhang Y, Yan B, et al. Quetiapine prevents oligodendrocyte and myelin loss and promotes maturation of oligodendrocyte progenitors in the hippocampus of global cerebral ischemia mice. J Neurochem. 2012 ; 123: 14-20
37. Xiao L, Xu H, Zhang Y, et al. Quetiapine facilitates oligodendrocyte development and prevents mice from myelin breakdown and behavioral changes. Mol Psychiatry. 2008 ; 13: 697-708
38. Zhang Y, Zhang H, Wang L, et al. Quetiapine enhances oligodendrocyte regeneration and myelin repair after cuprizone-induced demyelination. Schizophr Res. 2012 ; 138: 8-17
39. Linker RA, Lee DH, Ryan S, et al. Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway. Brain. 2011 ; 134: 678-692
40. Wang RR, Chen Y, Guo T, et al. Histamine H3 receptor negatively regulates oligodendrocyte differentiation and myelination. ACTRIMS/ECTRIMS MSBoston 2014: Poster Sessions 2 P621. Mult Scler. 2014 ; 20: 285-496
41. Saligrama N, Case LK, del Rio R, et al. Systemic lack of canonical histamine receptor signaling results in increased resistance to autoimmune encephalomyelitis. J Immunol. 2013 ; 191: 614-622
42. Mei F, Fancy SP, Shen YA, et al. Micropillar arrays as a high-throughput screening platform for therapeutics in multiple sclerosis. Nat Med. 2014 ; 20: 954-960
43. Yamaguchi W, Tamai R, Kageura M, et al. Sema4D as an inhibitory regulator in oligodendrocyte development. Mol Cell Neurosci. 2012 ; 49: 290-299
44. Giraudon P, Vincent P, Vuaillat C, et al. Semaphorin CD100 from activated T lymphocytes induces process extension collapse in oligodendrocytes and death of immature neural cells. J Immunol. 2004 ; 172: 1246-1255
45. Treps L, Le Guelte A, Gavard J. Emerging roles of semaphorins in the regulation of epithelial and endothelial junctions. Tissue Barriers. 2013 ; 1: e23272
46. Jonason A, Klimatcheva E, Fisher T, et al. Anti-SEMA4D antibody ameliorates pathogenic processes related to multiple sclerosis. ACTRIMS/ECTRIMS MSBoston 2014: Poster Sessions 2 P712. Mult Scler. 2014 ; 20: 285-496
47. Huang JK, Jarjour AA, Nait OB, et al. Retinoid X receptor gamma signaling accelerates CNS remyelination. Nat Neurosci. 2011 ; 14: 45-53
48. Sanders M, Medicetty S, Chandraratna R. IRX4204: A clinical stage, potent, and highly selective RXR agonist compound is brain penetrant, and promotes differentiation of oligodendrocyte precursor cells (OPCs) in vitro (S14.006). Neurology. 2014 ; 82: S14.006
49. Kabbinavar FF, Zomorodian N, Rettig M, et al. An open-label phase II clinical trial of the RXR agonist IRX4204 in taxane-resistant, castration-resistant metastatic prostate cancer (CRPC). 2014 Genitourinary Cancers Symposium. J Clin Oncol. 2014 ; 32 :
50. Bordet T, Buisson B, Michaud M, et al. Identification and characterization of cholest-4-en-3-one, oxime (TRO19622), a novel drug candidate for amyotrophic lateral sclerosis. J Pharmacol Exp Ther. 2007 ; 322: 709-720
51. Lenglet T, Lacomblez L, Abitbol JL, et al. A phase II-III trial of olesoxime in subjects with amyotrophic lateral sclerosis. Eur J Neurol. 2014 ; 21: 529-536
52. Magalon K, Zimmer C, Cayre M, et al. Olesoxime accelerates myelination and promotes repair in models of demyelination. Ann Neurol. 2012 ; 71: 213-226
53. Jurynczyk M, Jurewicz A, Bielecki B, et al. Inhibition of Notch signaling enhances tissue repair in an animal model of multiple sclerosis. J Neuroimmunol. 2005 ; 170: 3-10
54. Fancy SP, Kotter MR, Harrington EP, et al. Overcoming remyelination failure in multiple sclerosis and other myelin disorders. Exp Neurol. 2010 ; 225: 18-23
55. Fancy SP, Chan JR, Baranzini SE, et al. Myelin regeneration: A recapitulation of development?. Annu Rev Neurosci. 2011 ; 34: 21-43
56. Rosso SB, Sussman D, Wynshaw-Boris A, et al. Wnt signaling through Dishevelled, Rac and JNK regulates dendritic development. Nat Neurosci. 2005 ; 8: 34-42
57. Sato A, Khadka DK, Liu W, et al. Profilin is an effector for Daam1 in non-canonical Wnt signaling and is required for vertebrate gastrulation. Development. 2006 ; 133: 4219-4231
58. Ying Y, Tao Q. Epigenetic disruption of the WNT/beta-catenin signaling pathway in human cancers. Epigenetics. 2009 ; 4: 307-312